Background: Prescriptions of off-label under-and overdosing of direct oral anticoagulants
(DOACs) are common for patients with atrial fibrillation, but their efficacy and safety remain …

Background Several observational studies have shown that the inappropriate dosing use of
direct oral anticoagulants (DOACs) in atrial fibrillation (AF) that does not conform to …

Abstract Background Direct oral anticoagulants (DOACs) reduce the risk of stroke and
systemic embolism in patients with nonvalvular atrial fibrillation but may result in serious …

Aims Worldwide observational studies are evidencing discordance between guidelines and
real‐world practice regarding direct oral anticoagulant drug (DOAC) doses. This systematic …

Background: The use of direct oral anticoagulant (DOAC) off-label doses in atrial fibrillation
(AF) patients may result in poor clinical outcomes. However, the true prevalence remains …

Background The recommended doses for direct oral anticoagulants (DOACs) to prevent
stroke and systemic embolism (SE) in patients with atrial fibrillation (AF) are described in …

Abstract Background and Objectives Atrial fibrillation (AF) and the associated risk of stroke
are emerging epidemics throughout the world. Suboptimal use of oral anticoagulants for …

Background There are no head-to-head randomized controlled trials comparing different
direct oral anticoagulants (DOACs). Thus, we systematically reviewed and meta-analyzed …

Pivotal trials comparing direct oral anticoagulants (DOACs) against warfarin in patients with
atrial fibrillation (AF) predominantly involved patients with high stroke risk. This study aimed …

Background: Off-label dosing of direct oral anticoagulants (DOACs) is encountered clinically
among patients with atrial fibrillation (AF), although data on the clinical outcomes of over …